文献速递临床试验与 GCP

氨甲环酸与安慰剂在减少烧伤切除手术失血中的疗效:一项多中心、双盲、平行、随机安慰剂对照临床试验(TRANEX)

Efficacy of tranexamic acid versus placebo in reducing blood loss during burn excisional surgery: a multi-center, double-blind, parallel, randomized placebo-controlled clinical trial (TRANEX).
PubMed 文献 · Trials · 2024-08-02

本研究为多中心双盲随机安慰剂对照试验,计划纳入95例拟行烧伤切除手术且预计失血量≥250的成人患者,比较1500 mg氨甲环酸与安慰剂的疗效。主要终点为减少失血量,次要终点包括术中纤溶发生、移植皮片成活及凝血与血凝块形成差异。

要点

  • 拟纳入95例成人烧伤切除手术患者,干预组给予1500 mg氨甲环酸,对照组给予安慰剂。
  • 主要终点为失血量减少,研究按干预组失血量减少25%进行效能计算。
  • 次要终点包括术中纤溶发生、移植皮片成活及凝血与血凝块形成差异。

核心结论

  • 该随机对照试验方案旨在研究氨甲环酸减少烧伤切除手术失血量的疗效,并阐明烧伤创伤后及手术过程中的凝血状态。

研究设计与样本

  • 多中心双盲随机安慰剂对照临床试验,在荷兰烧伤中心开展。
  • 纳入拟行烧伤切除手术且预计失血量≥250的成人患者,共95例。
  • 干预组给予1500 mg氨甲环酸,对照组给予安慰剂。
  • 研究按干预组失血量减少25%进行效能计算。

主要发现

  • 主要终点为减少失血量。
  • 次要终点包括术中纤溶发生、移植皮片成活及凝血与血凝块形成差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite an increase in knowledge, blood loss during burn excisional surgery remains a major challenge and is an independent predictor of mortality. During burn surgery, limited measures are available to control the bleeding. Increased fibrinolysis could be one of the contributing factors of blood loss during burn excisional surgery. Tranexamic acid inhibits the fibrinolytic response, and a small body of evidence shows positive effects of tranexamic acid on the volume of blood loss. METHODS: The main objectives of this study are twofold, (1) to investigate whether tranexamic acid reduces blood loss and (2) to investigate the changes in coagulation after burn trauma and during burn excisional surgery. This study is a multicenter double-blind randomized clinical trial in patients scheduled for burn excisional surgery within the Dutch burn centers. All adult patients scheduled for burn surgery with an expected blood loss of ≥ 250 are eligible for inclusion in this study. The study is powered on a blood loss reduction of 25% in the intervention group. In total, 95 subjects will be included. The intervention group will receive 1500 mg tranexamic acid versus placebo in the other group. Primary endpoint is reduction of blood loss. Secondary endpoints include occurrence of fibrinolysis during surgery, graft take of the split skin graft, and differences in coagulation and blood clot formation. DISCUSSION: This protocol of a randomized controlled trial aims to investigate the efficacy of tranexamic acid in reducing blood loss during burn excisional surgery. Furthermore, this study aims to clarify the coagulation status after burn trauma and during the surgical process. TRIAL REGISTRATION: EudraCT: 2020-005405-10; ClinicalTrial.gov: NCT05507983 (retrospectively registered in August 2022, inclusion started in December 2021).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gigengack RK, Slob J, Vries AM, et al. Efficacy of tranexamic acid versus placebo in reducing blood loss during burn excisional surgery: a multi-center, double-blind, parallel, randomized placebo-controlled clinical trial (TRANEX). Trials. 2024. PMID: 39095919. doi:10.1186/s13063-024-08332-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。